<DOC>
	<DOCNO>NCT03098771</DOCNO>
	<brief_summary>To verify angiogenesis elderly patient atherosclerotic ischemia peripheral blood autologous CD34+ cell transplantation .</brief_summary>
	<brief_title>Peripheral Blood Autologous CD34+ Cell Transplantation Promotes Angiogenesis With Atherosclerotic Ischemia Elderly</brief_title>
	<detailed_description>History current related study Arteriosclerosis obliterans kind arterial lumen stenosis occlusive disease , cause continuous expansion arterial atherosclerosis secondary thrombosis . Clinical manifestation local skin temperature reduction , intermittent claudication , rest pain , ulcer difficult heal , gangrene infection.Some patient require amputation even life-threatening . Arteriosclerosis obliterans low limb commonly treat surgical treatment , endovascular treatment non-surgical treatment , effect satisfactory . For treatment arteriosclerosis obliterans , stem cell transplantation achieve great progress angiogenesis collateral circulation . There two main mechanism stem cell involve angiogenesis : ( 1 ) Promoting differentiation maturation new blood vessel home integration damage vascular plexus ; ( 2 ) Promoting angiogenesis ischemic tissue paracrine vascular endothelial growth factor ( VEGF ) .In recent year , discovery endothelial progenitor cell peripheral blood , concept angiogenesis renew . Transplantation endothelial progenitor cell bone marrow cell angiogenesis become focus research . Endothelial progenitor cell bone marrow cell transplantation use promote angiogenesis ischemic tissue order treat limb ischemia . Bone marrow stem cell mobilization use promote replication bone marrow stem cell , increase number endothelial progenitor cell peripheral blood , i.e. , number stem cell home ischemic tissue , finally accelerate speed magnitude angiogenesis . Fujisaki et al . confirm bone marrow cell mobilizers significantly stimulate bone marrow hematopoiesis increase number peripheral blood stem cells.Bone marrow cell mobilizer-recombinant human granulocyte colony stimulate factor ( rhG-CSF ) use mobilize bone marrow stem cell peripheral blood , increase number peripheral blood stem cell , especially endothelial progenitor cell , treat ischemic disease use transplant autologous stem cell , call autologous stem cell transplantation . Nevertheless , animal human experiment , proliferation potential influencing factor mobilize bone marrow stem cell peripheral blood endothelial progenitor cell ischemic tissue require investigation . Autologous stem cell transplantation transplant stem cell muscle ischemic limb , new capillary improve restore low limb blood flow , aim treat low limb ischemia . Endothelial progenitor cell hematopoietic stem cell think come common ancestor , call blood vessel stem cell . They express immature stem cell marker CD34 CD133 . Endothelial progenitor cell migrate bone marrow peripheral blood gradually lose CD133 , disappearance CD34 relatively slow . A large number basic clinical study confirm transplantation CD34+ cell promote angiogenesis ischemic limb experimental animal ( partial patient ) . Adverse event 1 . To record adverse event , include fever , infection , low limb pain ulcer , follow-up out-patient clinic . 2 . If severe adverse event occur , investigator report detail , include date occurrence measure take treat adverse event , principle investigator institutional review board within 24 hour . Data collection , management , analysis , open access 1 . Data collection : Case report form collect process use Epidata software ( Epidata Association , Odense , Denmark ) , collate , record electronically use double-data entry strategy . 2 . Data management : The locked electronic database accessible lock project manager . This arrangement alter . The Qingdao No . 9 People 's Hospital , China preserve data regard trial . 3 . Data analysis : A professional statistician statistically analyze electronic database create outcome analysis report submit lead researcher . An independent data monitoring committee supervise manage trial data , ensure scientific stringent trial yield accurate complete data . 4 . Data open access : Anonymized trial data publish www.figshare.com . Statistical analysis 1 . Statistical analysis perform use SPSS 19.0 software ( IBM , Armonk , NY , USA ) follow intention-to-treat principle . 2 . Normally distributed measurement data express mean , standard deviation , minimum maximum . Non-normally distributed measurement data express low quartile ( q1 ) , median upper quartile ( q3 ) . Count data express percentage . 3 . Kolmogorov-Smirnov test use determine normality measurement data . If data obey normal distribution , ABI , number microvessels low limb muscle number VEGF-immunoreactive cell compare two-sample t-test two group . Intragroup difference indicator compare use pair t-test 6 month transplantation . If data obey normal distribution , intergroup intragroup data compare use Mann Whitney U test Wilcoxon signed-rank test . The incidence adverse reaction compare Fisher 's exact probability test two group 6 month transplantation . 4 . The significance level Î± = 0.05 .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>Elderly patient arteriosclerosis obliterans ( Rutherford classification class 5 : slight tissue defect ; class 6 : tissue ulceration , gangrene ) Diabetic foot , Wagnar classification class 315 : deep ulcer , often affect bone tissue , deep abscess osteomyelitis Age range : 5060 year Irrespective gender Unilateral limb lesion Total occlusion main blood vessel No outflow tract distal artery Can perform open surgery endovascular surgery Signed informed consent Moderate severe liver kidney dysfunction Malignant tumor Hematological system diseases Rheumatic immune system diseases Poor stimulate effect colony stimulate factor Thromboangiitis obliterans Severe hyperthyroidism Endocrine metabolic disease severe hypothyroidism</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>